Insider Selling: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) SVP Sells 1,000 Shares of Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) SVP Krista Davis sold 1,000 shares of the business’s stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $60.00, for a total value of $60,000.00. Following the completion of the transaction, the senior vice president now directly owns 49,059 shares in the company, valued at approximately $2,943,540. This represents a 2.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

ANI Pharmaceuticals Stock Performance

NASDAQ:ANIP opened at $56.59 on Friday. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74. ANI Pharmaceuticals, Inc. has a 52-week low of $51.79 and a 52-week high of $70.81. The firm has a market cap of $1.19 billion, a price-to-earnings ratio of -102.89 and a beta of 0.73. The business’s fifty day moving average is $58.01 and its 200 day moving average is $60.33.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings data on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.09 by $0.25. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The company had revenue of $148.30 million for the quarter, compared to analyst estimates of $144.37 million. During the same period in the previous year, the company posted $1.05 EPS. The firm’s revenue for the quarter was up 12.5% compared to the same quarter last year. Research analysts predict that ANI Pharmaceuticals, Inc. will post 3.87 EPS for the current year.

Analyst Ratings Changes

ANIP has been the topic of several research reports. Truist Financial boosted their target price on ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a “hold” rating in a research note on Tuesday, October 22nd. Piper Sandler initiated coverage on ANI Pharmaceuticals in a research note on Friday, October 11th. They issued an “overweight” rating and a $68.00 target price on the stock. Raymond James boosted their target price on ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an “outperform” rating in a research note on Wednesday, September 18th. Leerink Partners initiated coverage on ANI Pharmaceuticals in a research note on Wednesday. They issued an “outperform” rating and a $80.00 target price on the stock. Finally, StockNews.com lowered ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, September 7th. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $77.71.

Hedge Funds Weigh In On ANI Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the business. Innealta Capital LLC bought a new position in ANI Pharmaceuticals in the 2nd quarter worth about $65,000. Ridgewood Investments LLC bought a new position in ANI Pharmaceuticals in the 2nd quarter worth about $85,000. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in ANI Pharmaceuticals by 24.2% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company’s stock worth $177,000 after acquiring an additional 579 shares during the last quarter. XTX Topco Ltd bought a new position in ANI Pharmaceuticals in the 2nd quarter worth about $207,000. Finally, Profund Advisors LLC bought a new position in ANI Pharmaceuticals in the 2nd quarter worth about $225,000. 76.05% of the stock is currently owned by institutional investors.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.